Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;54(11):3001-3007.
doi: 10.1007/s11255-022-03240-2. Epub 2022 May 28.

Compensatory elevated serum intermedin levels are associated with increased vascular calcification in hemodialysis patients

Wenhan Bao  1 , Lian He  2 , Aihua Zhang  3
Affiliations

Compensatory elevated serum intermedin levels are associated with increased vascular calcification in hemodialysis patients

Wenhan Bao et al. Int Urol Nephrol. 2022 Nov.

Abstract

Introduction: Vascular calcification (VC), which is a pathological process of abnormal calcium and phosphorus deposition in blood vessels, valves, heart and other tissues, is highly prevalent and predicts mortality in dialysis patients. Its mechanisms are complex and unclear. We presume that intermedin (IMD), a kind of small molecule active peptide, may play roles in VC in hemodialysis (HD) patients. This study aims to evaluate serum IMD levels and establish their relation to VC and other parameters in HD patients.

Methods: A total of 116 patients on maintenance HD treatment and 52 age- and sex-matched healthy controls were enrolled in this study. Serum IMD levels were measured by radioimmunoassay (RIA). VC was evaluated by abdominal aortic calcification scores.

Results: Serum IMD levels were significantly lower in HD patients than in controls [24.89 (13.55, 50.24) pg/ml vs. 137.79 (93.21, 201.64) pg/ml, P < 0.0001]. In addition, IMD was negatively correlated with the serum phosphate level (P = 0.036) in HD patients. However, compared with the group whose IMD levels were above the median, patients with IMD levels less than the median had a lower incidence of VC (P = 0.031). Multivariate logistic regression analyses revealed that serum IMD levels more than 24.89 pg/ml (P = 0.014, OR = 0.285), higher serum iPTH levels (P < 0.0001, OR = 1.093) and older age (P = 0.009, OR = 1.003) were significant independent determinant factors for VC in HD patients.

Conclusion: The serum IMD levels were significantly lower in HD patients than that in healthy group. In addition to higher PTH levels and older age, compensatory elevated IMD levels may be an independently determinant factor for VC in HD patients. This was the first study about IMD and VC in dialysis patients.

Keywords: Chronic kidney disease; Hemodialysis; Intermedin; Vascular calcification.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Gungor O, Kocyigit I, Yilmaz MI, Sezer S (2018) Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients. Semin Dial 31(1):72–81. https://doi.org/10.1111/sdi.12616 - DOI - PubMed
    1. He L, He WY, La-Ta A, Yang WL, Zhang AH (2018) Lower serum irisin levels are associated with increased vascular calcification in hemodialysis patients. Kidney Blood Press Res 43(1):287–295. https://doi.org/10.1159/000487689 - DOI - PubMed
    1. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY (2004) Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 279(8):7264–7274. https://doi.org/10.1074/jbc.M305332200 - DOI - PubMed
    1. Ni X, Zhang J, Tang C, Qi Y (2014) Intermedin/adrenomedullin2: an autocrine/paracrine factor in vascular homeostasis and disease. Sci Chin Life Sci 57(8):781–789. https://doi.org/10.1007/s11427-014-4701-7 - DOI
    1. Chang JR, Duan XH, Zhang BH, Teng X, Zhou YB, Liu Y, Yu YR, Zhu Y, Tang CS, Qi YF (2013) Intermedin1-53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway. Exp Biol Med (Maywood) 238(10):1136–1146. https://doi.org/10.1177/1535370213502619 - DOI

LinkOut - more resources